Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

By afschroeder • October 21, 2026

McInnes IB, Stein Gold L, Bissonnette R, Lebwohl MG, Reyes-Servin O, Cafone J, Yang YW, Chakravarty SD, Iaconangelo C, Li S, Shagroni T, Lozenski K, Armstrong AW, Merola JF. Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials. J Psoriasis Psoriatic Arthritis. 2026 Oct 18:24755303261494526. doi: 10.1177/24755303261494526. Epub ahead of print. PMID: 42898453; PMCID: PMC13677984.

Tags: Dermatology, icotrokinra, interleukin-23 inhibition, interleukin-23 receptor, oral peptide, patient-reported outcomes, plaque psoriasis, psoriatic arthritis, Publications

Ethical Considerations of Verbal Versus Written Consent for Minor Dermatologic Procedures

Moon JY, Zhou AE, Soriano T, Davis J, Kim J, Grant-Kels JM. Ethical Considerations of Verbal Versus Written Consent for Minor Dermatologic Procedures. J Am[...]

Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy

Zimmerman MP, Huang AY, Cox EK, Al Abosy R, Chong WL, Bastian AG, Vietor K, Choutri YA, Collier JL, Zhabotynsky V, Wang H, Fung M,[...]

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study

Paller AS, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]